🇺🇸 FDA
Pipeline program

Pentasa Sachet 2 g depotgranulat, Pentasa PLACEBO Sachet 2g in the granule formulation specifically designed to resemble the active drug product

Phase 2 small_molecule active

Quick answer

Pentasa Sachet 2 g depotgranulat, Pentasa PLACEBO Sachet 2g in the granule formulation specifically designed to resemble the active drug product for Lynch syndrome, which is increasing the risk of developing colorectal cancer is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Institut für biomedizinische Analytik NMR-Imaging GmbH
Indication
Lynch syndrome, which is increasing the risk of developing colorectal cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials